JP2019531074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531074A5 JP2019531074A5 JP2019515813A JP2019515813A JP2019531074A5 JP 2019531074 A5 JP2019531074 A5 JP 2019531074A5 JP 2019515813 A JP2019515813 A JP 2019515813A JP 2019515813 A JP2019515813 A JP 2019515813A JP 2019531074 A5 JP2019531074 A5 JP 2019531074A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- encoded
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 152
- 108091033319 polynucleotide Proteins 0.000 claims description 112
- 239000002157 polynucleotide Substances 0.000 claims description 112
- 102000040430 polynucleotide Human genes 0.000 claims description 112
- 210000002865 immune cell Anatomy 0.000 claims description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 102000023732 binding proteins Human genes 0.000 claims description 37
- 108091008324 binding proteins Proteins 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 108700026244 Open Reading Frames Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 108700019146 Transgenes Proteins 0.000 claims description 12
- 208000009527 Refractory anemia Diseases 0.000 claims description 11
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 206010066476 Haematological malignancy Diseases 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 230000002759 chromosomal effect Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010033661 Pancytopenia Diseases 0.000 claims description 6
- 208000024389 cytopenia Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 101150105332 TRBV7-9 gene Proteins 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 208000022769 mixed phenotype acute leukemia Diseases 0.000 claims description 4
- 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 claims description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims description 4
- 108010091373 HA-1 antigen Proteins 0.000 claims description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 3
- 101000772110 Homo sapiens T cell receptor alpha variable 21 Proteins 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 201000003791 MALT lymphoma Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 2
- 230000003416 augmentation Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 101150115896 TRAV21 gene Proteins 0.000 claims 2
- 101000666668 Homo sapiens T cell receptor beta diversity 1 Proteins 0.000 claims 1
- 101000645343 Homo sapiens T cell receptor beta joining 1-4 Proteins 0.000 claims 1
- 101000626659 Homo sapiens Taste receptor type 2 member 1 Proteins 0.000 claims 1
- 102100029487 T cell receptor alpha variable 21 Human genes 0.000 claims 1
- 102100038401 T cell receptor beta diversity 1 Human genes 0.000 claims 1
- 102100026272 T cell receptor beta joining 1-4 Human genes 0.000 claims 1
- 102100024845 Taste receptor type 2 member 1 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 description 10
- 102100027748 Rho GTPase-activating protein 45 Human genes 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 108700026220 vif Genes Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101150028671 TRAV10 gene Proteins 0.000 description 2
- 101150061758 TRAV17 gene Proteins 0.000 description 2
- 241000249096 Teschovirus Species 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101150091887 Ctla4 gene Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010091268 alpha-Macroglobulins Proteins 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003515 double negative t cell Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021065194A JP2021101734A (ja) | 2016-09-23 | 2021-04-07 | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399291P | 2016-09-23 | 2016-09-23 | |
| US62/399,291 | 2016-09-23 | ||
| PCT/US2017/053112 WO2018058002A1 (en) | 2016-09-23 | 2017-09-22 | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021065194A Division JP2021101734A (ja) | 2016-09-23 | 2021-04-07 | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531074A JP2019531074A (ja) | 2019-10-31 |
| JP2019531074A5 true JP2019531074A5 (https=) | 2020-11-12 |
| JP6866475B2 JP6866475B2 (ja) | 2021-04-28 |
Family
ID=61689729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515813A Active JP6866475B2 (ja) | 2016-09-23 | 2017-09-22 | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 |
| JP2021065194A Pending JP2021101734A (ja) | 2016-09-23 | 2021-04-07 | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021065194A Pending JP2021101734A (ja) | 2016-09-23 | 2021-04-07 | マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10538574B2 (https=) |
| EP (1) | EP3516044B1 (https=) |
| JP (2) | JP6866475B2 (https=) |
| KR (1) | KR102397771B1 (https=) |
| CN (1) | CN109996868A (https=) |
| AU (2) | AU2017331362B2 (https=) |
| BR (1) | BR112019005633A8 (https=) |
| CA (1) | CA3035075A1 (https=) |
| EA (1) | EA201990591A1 (https=) |
| IL (2) | IL265449B (https=) |
| MX (1) | MX2019003176A (https=) |
| WO (1) | WO2018058002A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019204683A1 (en) | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| CA3097396A1 (en) * | 2018-04-19 | 2019-10-24 | Baylor College Of Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
| EP3833681A1 (en) * | 2018-08-06 | 2021-06-16 | Medigene Immunotherapies GmbH | Ha-1 specific t cell receptors and their use |
| CN112996819B (zh) * | 2018-08-16 | 2025-11-04 | 纪念斯隆-凯特琳癌症中心 | 细胞分选系统及使用方法 |
| EP3836944A4 (en) | 2018-08-16 | 2022-05-11 | Memorial Sloan Kettering Cancer Center | LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE |
| CN109280086B (zh) * | 2018-09-10 | 2021-03-16 | 上海市公共卫生临床中心 | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 |
| NL2021789B1 (en) * | 2018-10-10 | 2020-05-14 | Academisch Ziekenhuis Leiden | Binding proteins specific for HA-1H and uses thereof |
| CA3119188A1 (en) | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| WO2020185796A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
| JP2022529433A (ja) * | 2019-04-15 | 2022-06-22 | ロジックバイオ セラピューティクス， インコーポレイテッド | 遺伝子療法をモニタリングする |
| CN110128528B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| SG11202111865UA (en) * | 2019-05-01 | 2021-11-29 | Pact Pharma Inc | Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy |
| WO2020243134A1 (en) * | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| JP7737978B2 (ja) | 2019-08-20 | 2025-09-11 | フレッド ハッチンソン キャンサー センター | Ｗｔ－１に特異的なｔ細胞免疫療法 |
| CA3168729A1 (en) * | 2020-02-24 | 2021-09-02 | Melinda MATA | Methods for expanding t cells for the treatment of cancer and related malignancies |
| CN111499767B (zh) * | 2020-06-15 | 2020-09-29 | 华夏英泰（北京）生物技术有限公司 | 一种合成t细胞受体抗原受体复合物及其应用 |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| CN116724053A (zh) | 2020-09-24 | 2023-09-08 | 弗雷德哈钦森癌症中心 | 靶向sox2抗原的免疫治疗 |
| EP4240490A4 (en) * | 2020-11-06 | 2025-06-18 | Tscan Therapeutics, Inc. | Binding proteins for the recognition of the HA-1 antigen and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| TW202241938A (zh) * | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| JP2024514522A (ja) | 2021-04-07 | 2024-04-02 | センチュリー セラピューティクス，インコーポレイテッド | 遺伝子導入ベクターおよび細胞を操作する方法 |
| WO2022216624A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| BR112023018844A2 (pt) | 2021-04-07 | 2023-10-10 | Century Therapeutics Inc | Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas |
| WO2022235577A2 (en) * | 2021-05-03 | 2022-11-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1 |
| WO2023086995A2 (en) * | 2021-11-12 | 2023-05-19 | Imanis Life Sciences, Llc | Genetically modified ungulate cells and their uses in cancer therapy |
| AU2022423987A1 (en) | 2021-12-29 | 2024-07-11 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| CN119698467A (zh) | 2022-06-08 | 2025-03-25 | 世纪治疗股份有限公司 | 衍生自遗传工程化以具有膜结合的il12的诱导多能干细胞的免疫效应细胞及其用途 |
| US20250090582A1 (en) | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
| AU2023375625A1 (en) | 2022-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| WO2024168160A2 (en) * | 2023-02-08 | 2024-08-15 | Clade Therapeutics, Inc. | Cd4 + and cd8 + single positive t cells and compositions and methods for generating the same |
| WO2024263991A2 (en) * | 2023-06-22 | 2024-12-26 | Arc Research Institute | Methods and compositions for integration deficient viral vectors |
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025117773A2 (en) * | 2023-11-30 | 2025-06-05 | Affini-T Therapeutics, Inc. | Compositions and methods for treating neoplasia |
| WO2025207795A1 (en) | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207798A1 (en) | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025231299A1 (en) * | 2024-05-02 | 2025-11-06 | Fred Hutchinson Cancer Center | Tcr t cell therapy targeting ha-1 |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US20040092446A1 (en) * | 1997-07-23 | 2004-05-13 | Goulmy Elsa A.J.M. | HA-1 epitopes and uses thereof |
| AU756962B2 (en) * | 1997-07-23 | 2003-01-30 | Rijksuniversiteit Te Leiden | The HA-1 antigen |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| AU2003215869B2 (en) | 2002-03-15 | 2008-04-24 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| WO2003106692A2 (en) * | 2002-06-13 | 2003-12-24 | Merck Patent Gmbh | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| DK1910521T3 (da) * | 2005-08-05 | 2011-02-07 | Helmholtz Zentrum Muenchen | Generering af allo-begrænsede, antigenspecifikke T-celler |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US20090275642A1 (en) * | 2006-10-06 | 2009-11-05 | Reisfeld Ralph A | Dna composition for eliciting an immune response against tumor-associated macrophages |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| WO2014160902A1 (en) * | 2013-03-27 | 2014-10-02 | Fred Hutchinson Cancer Research Center | Directed immune stimulation |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| WO2016040724A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| JP6718444B2 (ja) | 2014-11-03 | 2020-07-08 | アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） | Ｂｏｂ１に対して指向されるＴ細胞レセプターおよびその使用 |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| CA2978171A1 (en) * | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
-
2017
- 2017-09-22 CN CN201780058434.9A patent/CN109996868A/zh active Pending
- 2017-09-22 EP EP17854051.4A patent/EP3516044B1/en active Active
- 2017-09-22 BR BR112019005633A patent/BR112019005633A8/pt not_active Application Discontinuation
- 2017-09-22 MX MX2019003176A patent/MX2019003176A/es unknown
- 2017-09-22 JP JP2019515813A patent/JP6866475B2/ja active Active
- 2017-09-22 EA EA201990591A patent/EA201990591A1/ru unknown
- 2017-09-22 WO PCT/US2017/053112 patent/WO2018058002A1/en not_active Ceased
- 2017-09-22 AU AU2017331362A patent/AU2017331362B2/en active Active
- 2017-09-22 KR KR1020197007945A patent/KR102397771B1/ko active Active
- 2017-09-22 CA CA3035075A patent/CA3035075A1/en active Pending
-
2019
- 2019-03-18 IL IL265449A patent/IL265449B/en unknown
- 2019-03-22 US US16/362,551 patent/US10538574B2/en active Active
- 2019-12-02 US US16/700,998 patent/US20200231649A1/en not_active Abandoned
-
2021
- 2021-04-07 JP JP2021065194A patent/JP2021101734A/ja active Pending
- 2021-10-28 IL IL287686A patent/IL287686A/en unknown
-
2023
- 2023-08-25 US US18/456,389 patent/US20240279307A1/en active Pending
-
2025
- 2025-04-17 AU AU2025202743A patent/AU2025202743A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531074A5 (https=) | ||
| JP7273421B2 (ja) | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 | |
| US20240392245A1 (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Brischwein et al. | Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class | |
| US20180002427A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| JP2021519072A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| RS66264B1 (sr) | Genska terapija | |
| RS61223B1 (sr) | Označeni himerni efektorski molekuli i njihovi receptori | |
| JP7591405B2 (ja) | ユニバーサル抗原提示細胞およびその使用 | |
| CA3083324A1 (en) | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins | |
| JP2021500024A (ja) | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| AU2022263573B2 (en) | Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof | |
| CN112442509A (zh) | Cd19-cd20双特异性和双通道car-t及其使用方法 | |
| EP4532727A2 (en) | Compositions and methods comprising chimeric adaptor polypeptides | |
| NL2021789B1 (en) | Binding proteins specific for HA-1H and uses thereof | |
| JP2024541976A (ja) | キメラアダプターポリペプチド | |
| Wang et al. | Immunotherapy of cancer | |
| KR102961312B1 (ko) | CAR를 발현하는 면역세포와 항원제시세포를 맺어주는 이종(allogeneic) 폴리펩타이드 및 이의 용도 | |
| US20250281614A1 (en) | Chimeric receptors comprising interleukin 7 receptor (il7r) domains | |
| Cording et al. | Innate Immune Cell Engagers: Matchmakers for Next-Generation Immunotherapy | |
| WO2025098399A1 (zh) | 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用 | |
| EP4701651A2 (en) | Coreceptor chimeric antigen receptor | |
| DeSantes et al. | Immunotherapy of cancer | |
| EA046120B1 (ru) | Генная терапия |